GAITHERSBURG, Md.--(EON: Enhanced Online News)--MaxCyte, Inc., the pioneer in scalable, high performance cell transfection systems, is holding a series of events at Cambridge Health Institute’s Fifth Annual PEGS Europe Protein & Antibody Engineering Summit to be held November 4-8, 2013, at the Sheraton Hotel & Spa in Lisbon, Portugal. MaxCyte will present data in both podium and poster presentations emphasizing the universality of MaxCyte flow electroporation for the rapid, high titer production of antibodies and other proteins such as bi-specific antibodies, recombinant proteins, VLPs, and viral vectors. Data will also be presented highlighting the application of MaxCyte electroporation in high-efficiency, rapid downstream generation of stable cell lines. MaxCyte scientists will be available throughout the conference at Booth #3 to demonstrate the operation of the MaxCyte STX and MaxCyte VLX instruments and to provide further technical details about the use of flow electroporation for large scale transient gene expression and rapid stable cell line generation.
“Industry leaders look to MaxCyte’s flow electroporation at all stages of biotherapeutic development. MaxCyte’s technology enables a rapid, reliable, and cost effective platform for production of multi-gram quantities of antibodies and other proteins from the earliest stages of development, characterization, and screening to a final production process”
Dr. Peer Heine, Field Applications Scientist at MaxCyte, will present data on flow electroporation in a podium presentation entitled “Scaling from the Bench to Biomanufacturing: Large Scale CHO Transient Transfection Using Flow Electroporation” on Wednesday, November 6, at 12:05 PM, within the Optimizing Protein Expression Track.
“Industry leaders look to MaxCyte’s flow electroporation at all stages of biotherapeutic development. MaxCyte’s technology enables a rapid, reliable, and cost effective platform for production of multi-gram quantities of antibodies and other proteins from the earliest stages of development, characterization, and screening to a final production process,” says Douglas Doerfler, President and CEO of MaxCyte. “Dr. Heine’s conference presentation highlights how MaxCyte transfection can accelerate timelines and improve development outcomes.”
“MaxCyte flow electroporation is a unifying technology that simplifies product and process development from the bench to biomanufacturing,” says Dr. Karen Donato, Executive Vice President of Global Business Development & Marketing at MaxCyte. “Comparable transfection performance and protein expression are maintained over a range of microliters to hundreds of liters of culture. This combination of performance, flexibility, and scalability truly sets MaxCyte flow electroporation apart from other transfection methods.”
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, for rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.
For more information, http://www.maxcyte.com.